Phase 3 open-label, randomized, controlled study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001) Meeting Abstract
| Authors: | Galsky, M. D.; Grande, E.; Necchi, A.; Koontz, M. Z.; Iyer, G.; Campbell, M. T.; Drakaki, A.; Loriot, Y.; Sokolowski, K. M.; Zhang, W.; Powles, T. |
| Abstract Title: | Phase 3 open-label, randomized, controlled study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001) |
| Meeting Title: | 2024 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2024 Jan 25-27 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-02-01 |
| Language: | English |
| ACCESSION: | WOS:001266676900047 |
| DOI: | 10.1200/JCO.2024.42.4_suppl.TPS717 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS717 -- Source: Wos |
